

SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2012-11-29** | Period of Report: **2012-11-12**

SEC Accession No. [0001144204-12-065647](#)

([HTML Version](#) on [secdatabase.com](#))

REPORTING OWNER

Blachman Amir

CIK: **1509562**

Type: **4** | Act: **34** | File No.: **000-53071** | Film No.: **121232913**

Mailing Address
*TARGETED MEDICAL
PHARMA, INC.
2980 BEVERLY GLEN
CIRCLE, SUITE 301
LOS ANGELES CA 90077*

ISSUER

Targeted Medical Pharma, Inc.

CIK: **1420030** | IRS No.: **205863618** | Fiscal Year End: **1209**

SIC: **6770** Blank checks

Mailing Address
*2980 BEVERLY GLEN
CIRCLE
SUITE 301
LOS ANGELES CA 90077*

Business Address
*2980 BEVERLY GLEN
CIRCLE
SUITE 301
LOS ANGELES CA 90077
310-474-9809*

FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: 02/28/2011
Estimated average burden hours per response 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Blachman Amir			2. Issuer Name and Ticker or Trading Symbol Targeted Medical Pharma, Inc. [NONE]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ☐ Director ☐ 10% Owner ☒ Officer (give title below) ☐ Other (specify below) See Remarks	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/12/2012			
C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301						
(Street) LOS ANGELES, CA 90077			4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing (Check applicable line) ☒ Form Filed by One Reporting Person ☐ Form Filed by More than One Reporting Person	
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/12/2012		<u>M</u>		2,396	A	\$3.38	2,396	D	
Common Stock	11/12/2012		<u>M</u>		23,958	A	\$3.38	23,958	D	
Common Stock	11/12/2012		<u>F</u>		54,986	D	\$5	26,354	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options to Purchase Common Stock	\$3.38	11/12/2012		<u>M</u>			7,395	05/16/2010	05/16/2020	Common Stock	7,395	\$ 0	0	D	
Options to Purchase	\$3.38	11/12/2012		<u>M</u>			73,945	(1)	07/28/2020	Common Stock	73,945	\$ 0	0	D	

Common Stock															
-----------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Explanation of Responses:

1. These options vested on a monthly basis in equal installments over a two-year period beginning 07/28/2012

Remarks:

VP of Strategy and Operations, Chief Compliance and Ethics Officer and Secretary

Signatures

/s/ Amir Blachman

** Signature of Reporting Person

11/12/2012

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.